13th International Rotavirus Symposium Presentations
Opening Session
Welcome and Introduction - Amy Finan
Opening Remarks - Natalia Zhukova
Introduction of Roger Glass Lecture - Gagandeep Kang
Fourth Roger Glass Lecture - Umesh Parashar
Session I: Global Burden of Rotavirus Disease
Global Burden of Disease study among children under 5 years - Christopher Troeger
Global Pediatric Diarrhea Surveillance network demonstrates what pathogens are associated with acute diarrhea in children - Adam Cohen
Etiology of diarrheal disease after rotavirus vaccine introduction - Karen Kotloff
The cost effectiveness of RV vaccination in Gavi countries - Frederic Debellut
Session II: Global Impact & Safety of rotavirus vaccines
Effectiveness of a monovalent vaccine on rotavirus-associated diarrheal disease hospitalization in Kenyan children - Sammy Khagayi
Effectiveness of monovalent Rotavirus Vaccine in the Philippines - Anna Lopez
Annual variation in direct and indirect effects and total impact of rotavirus vaccination among children in the US - Julia Baker
Intussusception surveillance in India - Gagandeep Kang
Rotavirus Vaccines and intussusception. What is the latest data? - Jacqueline Tate
Session III: Burden of rotavirus disease and impact in the European Region
Regional Update - Danni Daniels
EuroRotaNet update - Miren Iturriza-Gomara
Country Spotlight: Tajikistan - Anvar Nazurdinov
Country Spotlight: Germany - Judith Koch
Poster: Early results on impact of rotavirus vaccine in Uzbekistan - Renat Latipov
Session IV: Barriers and enablers to rotavirus vaccine introduction
Belarus - Irina Glinskaya
Estonia - Natalia Kerbo
Strict age limits for rotavirus vaccination: experience from Norway - Terese Bekkevold
Montenegro - Senad Begic
Session V: Advances in rotavirus immunology & virology
New insights regarding humoral immunity to human rotaviruses - Harry Greenberg
Susceptibility to rotavirus infections - Mary Estes
Rotavirus vaccines and the micro biome - Vanessa Harris
Poster: Non-secretor Histo-blood Group Antigen Phenotype Does Not Impair Susceptibility To Infection With Rotarix Vaccine Among Infants In Bangladesh - Benjamin Lee
Session VI: Current rotavirus vaccines in routine immunization
RotaTeq (Pentavalent human-bovine (WC3) rotavirus vaccine) - An update - Ritapurna Das
The benefits of rotavirus vaccination with human rotavirus vaccine; lessons learned from impact data 2006-2017 - Bernd Benninghoff
ROTAVAC – Product Development and Programmatic Implementation - Sai Prasad
Updates on ROTASILL development - Sajjad Desai
Session VII: Innovative vaccine approaches for rotavirus
Phase 2 immune responses of a subunit rotavirus vaccine - Michelle Groome
RV3-BB vaccine protects against severe, very severe and all-severity rotavirus disease from birth - Julie Bines
An oral, live attenuated, pentavalent (G1-G4 and P1[8]), Heat-Stable Rotavirus Vaccine (HSRV) presented in a single container/closure delivery device - Davinder Gill
Development of a VP6 subunit rotavirus vaccine - Vesna Blazevic
Recent advances in inactivated rotavirus vaccine development - Baoming Jiang
Development of the RV3-BB vaccine at Biofarma - Erman Tritama
Session VIII: Ruth Bishop Lecture
Introduction of Ruth Bishop Lecture - Julie Bines
Ruth Bishop Keynote Lecture - Ulrich Desselberger
Session IX: Poster Highlights
Household transmission of rotavirus in Malawian children with acute gastroenteritis is associated with disease severity - Aisleen Bennett
Neonatal rotavirus infection and impact on rotavirus vaccine immune response - Sudhir Babji
Rotavirus vaccine take in infants predicted by secretor status - George Armah
Modulation of neonatal rotavirus infection by human mild oligosaccharides, milk microbiome and infant gut microbiome - Sasirekha Ramani
Session X: Innovative strategies to increase impact
Total Systems Effectiveness (TSE) Pilot: developing the country use case using rotavirus vaccines as a case study - Birgitte Giersing
Novel Primary Containers/ Delivery Devices - Darin Zehrung
User empowerment initiatives to address coverage gaps - Lora Shimp
Alternative immunization schedules / risk benefit - Carl Kirkwood
Session XI: Vaccine economics & financing
Cost-effectiveness and benefit-risk of rotavirus vaccination 21 Middle Income Countries in the European Region - John Farrow
The cost effectiveness of RV vaccination in Ghana - Justice Nonvignon
The cost effectiveness of RV vaccination in Mongolia - Luvsan Munkh-Erdene
Achievements of financial sustainability of the immunization program in countries that are leaving GAVI support - Vladimir Getia
How to “Boost” Introduction of Vaccines into Routine Immunization Programs: implications of procurement approaches on program costs - Gideon Chelule
Session XII: Remaining programmatic challenges for the implementation of rotavirus vaccines
Interchangeability of RVV products - Daniel Payne
Making sure rota virus vaccines actually get delivered to those who need them most - Craig Burgess
Addressing vaccine hesitancy and reaching vulnerable populations: Lessons from the Tailoring Immunization Programs approach - Sanjin Musa
Rotavirus vaccine impact beyond preventing diarrhea - Samir Saha
Closing Message - Mathuram Santosham